Loading
A small French trial showed weekly paclitaxel controls angiosarcoma in most patients for a few months, making it the standard drug for this rare vascular cancer.
ANGIOTAX was a single-arm phase 2 trial of the French Sarcoma Group in which 30 patients with unresectable or metastatic angiosarcoma received weekly paclitaxel 80 mg/m2. Most patients were free of progression at two months, the primary endpoint, with responses concentrated in cutaneous scalp and face angiosarcoma, and toxicity was mild. Published in the Journal of Clinical Oncology in 2008, it made weekly paclitaxel the reference systemic treatment for angiosarcoma; the successor ANGIOTAX-PLUS trial found that adding bevacizumab did not improve outcomes.
Shares French Sarcoma Group, Sarcomas (soft tissue, bone, GIST), Cytotoxic chemotherapy and the tag subtype-page.
Shares Angiosarcoma, Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma), Paclitaxel / nab-paclitaxel and the tag subtype-page.
Shares Sarcomas (soft tissue, bone, GIST), Cytotoxic chemotherapy and the tag subtype-page.
Shares French Sarcoma Group, Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma), Sarcomas (soft tissue, bone, GIST) and the tag subtype-page.
Shares French Sarcoma Group, Sarcomas (soft tissue, bone, GIST) and the tag subtype-page.
Shares Sarcomas (soft tissue, bone, GIST) and the tag subtype-page.
Shares Sarcomas (soft tissue, bone, GIST) and the tag subtype-page.
Shares Sarcomas (soft tissue, bone, GIST) and the tag subtype-page.